Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

B 002

Next Previous
Drug Profile

B 002

Alternative Names: B-002; HER-2 monoclonal antibody - Shanghai Pharmaceuticals Holding; Humanised anti-HER2 monoclonal antibody compound for injection - Shanghai Pharmaceuticals Holding

Latest Information Update: 28 Jul 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shanghai Pharmaceuticals Holding
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported HER2 positive breast cancer

Most Recent Events

  • 28 Jul 2024 No recent reports of development identified for phase-I development in HER2-positive-breast-cancer(Metastatic disease, Second-line therapy or greater) in China (IV, Infusion)
  • 12 Jul 2022 B 002 is still in phase-I development for Her2 positive Breast-cancer(Metastatic disease, Second-line therapy or greater) in China (IV, Infusion) (Shanghai Pharmaceutical Group pipeline, July 2022)
  • 28 Jun 2022 No recent reports of development identified for phase-I development in Her2 positive Breast-cancer(Metastatic disease, Second-line therapy or greater) in China (IV, Infusion)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top